Supplementary Figure S4 from Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma

crossref(2023)

引用 0|浏览4
暂无评分
摘要

Supplementary Figure S4: Effect of sorafenib with or without iRGD on MAPK phosphorylation levels in the HepG2 xenografts from the different treatment groups.

更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要